Gossamer Bio, Inc. - 8-K Filing
Gossamer Bio exchanged $181.05 million in 5% convertible notes for new 7.5% secured first lien notes, 254.15 million shares of common stock, 33.4 million prefunded warrants, and 135.79 million purchase warrants on June 4, 2026. The remaining $18.95 million in existing notes will be offered until June 16, with a final settlement expected on June 18. (Items: 1.01 Entry into a Material Definitive Agreement, 1.02 Termination of a Material Definitive Agreement, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, 3.02 Unregistered Sales of Equity Securities)
Tickers: $GOSS